Today's Endpoints News Lead Article Regarding Eli Lilly Actions and Plans, page-22

SunnyKabs, I do hope that you got this wrong and I think you hope also in the same way. ATH has been telling a very long time to start phase 2 in the second half of this year and again today Kempler tells: "Whilst the opportunity for our therapies is only growing, we remain highly focused on the current goal to advance ATH434 to a Phase 2 study later this calendar year".

IMO they need to have visibility for at least 4 months.

Kempler continues: "Whilst the opportunity for our therapies is only growing, we remain highly focused on the current goal to
advance ATH434 to a Phase 2 study later this calendar year. We continue to collect vital observational
data in our natural history study of MSA, BioMUSE, which has exceeded its original enrollment goals and
has been expanded. These data have allowed us to understand how the disease behaves in our target
patient population so we can optimize the design our Phase 2 trial related to patient population and
endpoints, and thereby maximizing the chance of success".

So it looks like they are more than ready. They have been optimizing the study for a very long time, It must be ready to start. That is the very issue why Stamler was hired for and he had previous experience.

With PBT2 it is more difficult to say anything but these 8 months passed is already a long time to negotiate a sales deal to save perhaps even 700.000 lives. 12 months more would indicate that the negotiators do not understand the antibiotic-resistant problem at all growing up to 10 million deaths in 2050. But let us see. I really want that your prediction will be wrong.